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Background Circulating endothelial progenitor cells (EPCs) are
thought to play a pivotal role in endothelial repair. Clinical
trials utilising EPCs to promote therapeutic angiogenesis are
already underway Previous reports suggest a reduced EPC
number and impaired functional activity in patients with type
2 diabetes mellitus. However, the actual identity of the cell
type involved and the functional role played in the repair
process needs to be further defined before EPCs can be suc-
cessfully utilised in the clinic. In the present study, we assessed
the functional capacity of circulating late out-growth endothe-
lial progenitor cells (OECs) to further assess the contribution
of the diabetic environment to diminished OEC function in
the context of wound healing.
Methods and results OECs were isolated from 7 diabetic
patients, presenting with ulcers ranging in size from 60 mm3–
2500 mm3. OECs were characterised as CD34+, CD31+,
vWF+, positive for AcLDL and UEA uptake and negative for
the hematopoietic marker CD45 by immunohistochemistry.
Migration of CD34+ OECs, evaluated by a scratch assay, dem-
onstrated that migration is impaired in diabetic OECs com-
pared to healthy control OECs, with 40–42% closure vs
100% over 24 h respectively. In addition, achemotaxis trans-
well migration assay showed a decreased response to SDF-1
by diabetic cells vs healthy OECs. An angiogenesis tube for-
mation assay also established a reduced capacity of the dia-
betic OECs to form an endothelial network as compared to
healthy OECs (p < 0.0001), measured using the closed loop
perimeter, and the number of branch points (p < 0.05).
Nitrite concentrations were measured using a Griess assay, and
the results showed that diabetic OECs produced less nitric
oxide as compared to healthy OECs (p < 0.0005).
Conclusion OECs from diabetic patients show an impaired
migration and response to chemotactic agents in vitro com-
pared to OECs isolated from healthy controls. In addition, the
reduced nitric oxide bioavailability found by diabetic cells may
contribute to OEC dysfunction in diabetes. Future work will
focus on assessing the secretome of healthy vs diabetic OECs.
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Vascular calcification is implicated in a range of cardiovascular
disease mechanisms, leading to an associated increase in
morbidity and mortality. One such trigger are advanced glyca-
tion endproducts (AGEs), the tissue accumulation of which
increases with age and is more prevalent in diabetic subjects
due to oxidative stress and poor glycaemic control. The aim
of this study was to investigate the osteogenic potential of
AGEs and elucidate mechanisms of inhibiting these processes
in a smooth muscle cell (SMC) culture model.
Osteogenic differentiation of SMCs was induced using Î²-
glycerophosphate (Î²-GP), carboxymethyllysine (CML), carbox-
yethyllysine (CEL) methylglyoxal (MGO) and glycated low
density lipoprotein (gly-LDL). The cells were subsequently
treated with aminoguanidine (AG), an inhibitor of AGE for-
mation, and novel glycomimetic compounds in order to deter-
mine their anti-calcification potential in vitro using qPCR,
ELISA, Alkaline phosphatase (ALP) activity and Alizarin red
staining.
Gly-LDL (10 mg/ml) and CML (2.5nM) increased the level
of calcification observed compared to the Î²-GP (5 mM) posi-
tive control after 21 days (p < 0.05), with gly-LDL induced
calcification apparent after 14 days. Both AG (250 mM) and
the novel glycomimetic compounds reduced the level of min-
eralisation observed at 21 days compared with osteogenic
treatments (p < 0.05). CEL (2.5 nM) and MGO (0.1 mM)
both induced calcification, however mineralization was not as
extensive as with Î²-GP. When compared to the structure of
CML, the side-chain of CEL contains an extra methyl group,
suggesting this group impacts RAGE receptor binding. It was
also shown that Î²-GP combined with increased glucose con-
centration induced more extensive calcification unlike low glu-
cose levels and Î²-GP alone. ALP activity, when stimulated
with Î²-GP, CML and gly-LDL was greater at day 4 than at
day 7, with AG reducing ALP activity measurements at day 4.
Gly-LDL increases gene expression of OCN at day 4 com-
pared with Î²-GP and CML, however this was reduced at day
7, corresponding with an increased expression of OPN and
OPG. NOTCH-3 gene expression was also reduced at day 7.
Gene expression of OPN, OPG and NOTCH-3 were reduced
at both day 4 and day 7 compared with osteogenic treatments
(Î²-GP, CML and gly-LDL).
In summary, we conclude that gly-LDL and CML are
potent inducers of calcification compared with Î²-GP, and that
their osteogenic potential can be modulated by both AG and
novel glycomimetic compounds.
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Background/objective We have recently reported that micro-
RNA-22 (miR-22) regulates vascular smooth muscle cell
(VSMC) differentiation from stem cells in vitro and in vivo.
However, little is known about the functional involvements of
miR-22 in VSMC functions and vessel injury-induced neoin-
tima formation. In the current study, we aimed to establish
the causal role of miR-22 and its target genes in VSMC pro-
liferation, migration and neointima lesion formation.
Methods and results miR-22 was significantly down-regulated
in VSMCs upon various pathological stimuli, and in injured
arteries. miR-22 over-expression in serum-starved VSMCs
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